Literature DB >> 15853435

Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature.

Helen Doll1, Marc Miravitlles.   

Abstract

There is a lack of emphasis on health-related QOL (HR-QOL) changes associated with acute exacerbation of chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD). The aim of this review is to examine the use of HR-QOL instruments to evaluate acute exacerbation of CB or COPD, so as to form recommendations for future research.A literature search of papers published between 1966 and July 2003 identified more than 300 articles that used acute exacerbation of CB or COPD as the search term. However, only 21 of these studies employed HR-QOL measures as predictors of outcome or in the assessment of the impact, evolution or treatment of acute exacerbations of COPD or CB. A variety of HR-QOL measures were used, both generic and disease specific. The disease-specific St George's Respiratory Questionnaire (SGRQ), devised for patients with stable CB and with a recall period of 1-12 months, was the most widely used measure, with the Chronic Respiratory disease Questionnaire (CRQ) and the Baseline and Transitional Dyspnoea Index (BDI, TDI) being the only other disease-specific measures used. Most measures, both generic and disease specific, performed adequately when used during acute exacerbation of CB or COPD and indicated poor HR-QOL during acute exacerbation, which improved on resolution of the exacerbation. Relationships were evident between HR-QOL during an acute exacerbation and various outcomes, including post-exacerbation functional status, hospital re- admission for acute exacerbation or COPD, and mortality. There is a need for studies of treatments for acute exacerbation of CB or COPD to include an appropriate HR-QOL instrument to aid in the stratification of patients so as to target the right treatment to the right patient group. While a new instrument could be developed to measure HR-QOL during acute exacerbation of CB or COPD, currently available disease-specific measures such as the CRQ and the SGRQ appear to be acceptable to patients during acute exacerbation. However, the recall period of the SGRQ symptoms component should be shortened to make it more appropriate for use during acute exacerbation.

Entities:  

Mesh:

Year:  2005        PMID: 15853435     DOI: 10.2165/00019053-200523040-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  96 in total

1.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

Review 2.  Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed?

Authors:  C Sohy; C Pilette; M S Niederman; Y Sibille
Journal:  Eur Respir J       Date:  2002-05       Impact factor: 16.671

Review 3.  Antibiotic therapy in acute exacerbations of chronic bronchitis.

Authors:  S G Adams; A Anzueto
Journal:  Semin Respir Infect       Date:  2000-09

4.  Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.

Authors:  J Lorenz; I M Thate-Waschke; O Mast; R Kubin; R Rychlik; T Pfeil; D Daniel; G S Tillotson
Journal:  J Int Med Res       Date:  2001 Mar-Apr       Impact factor: 1.671

5.  An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.

Authors:  M Rutten-van Mölken; B Roos; J A Van Noord
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

6.  Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors.

Authors:  Y Chen; K Breithaupt; N Muhajarine
Journal:  J Clin Epidemiol       Date:  2000-07       Impact factor: 6.437

Review 7.  Treatment of chronic obstructive pulmonary disease in older patients: a practical guide.

Authors:  Abebaw M Yohannes; Christopher C Hardy
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 9.  Treatment of COPD exacerbations. Pharmacologic options and modification of risk factors.

Authors:  Amy R Blanchard
Journal:  Postgrad Med       Date:  2002-06       Impact factor: 3.840

Review 10.  Infection in acute exacerbations of chronic bronchitis: a clinical perspective.

Authors:  R C Read
Journal:  Respir Med       Date:  1999-12       Impact factor: 3.415

View more
  45 in total

1.  Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry.

Authors:  Martin K Johnson; Malcolm Birch; Roger Carter; John Kinsella; Robin D Stevenson
Journal:  Thorax       Date:  2006-11-14       Impact factor: 9.139

Review 2.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

3.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

4.  Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Levent Cem Mutlu; Nejat Altintas; Murat Aydin; Feti Tulubas; Mustafa Oran; Volkan Kucukyalin; Gizem Kaplan; Ahmet Gurel
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

5.  Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.

Authors:  Marc Miravitlles; Carles Llor
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

7.  Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life.

Authors:  Marc Miravitlles; Carles Llor; Jesús Molina; Karlos Naberan; Josep M Cots; Fernando Ros
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

8.  Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.

Authors:  Petra Menn; Norbert Weber; Rolf Holle
Journal:  Health Qual Life Outcomes       Date:  2010-04-15       Impact factor: 3.186

Review 9.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 10.  Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies.

Authors:  Marc Miravitlles; Antonio Anzueto
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.